{
    "id": "1602856",
    "revid": "42941688",
    "url": "https://en.wikipedia.org/wiki?curid=1602856",
    "title": "Granzyme B",
    "text": "Granzyme B (GrB) is a &lt;a href=\"serine%20protease\"&gt;serine protease&lt;/a&gt; most commonly found in the granules of &lt;a href=\"natural%20killer%20cells\"&gt;natural killer cells&lt;/a&gt; (NK cells) and &lt;a href=\"cytotoxic%20T%20cells\"&gt;cytotoxic T cells&lt;/a&gt;. It is secreted by these cells along with the pore forming protein &lt;a href=\"perforin\"&gt;perforin&lt;/a&gt; to mediate &lt;a href=\"apoptosis\"&gt;apoptosis&lt;/a&gt; in target cells.\nGranzyme B has also more recently found to be produced by a wide range of non-cytotoxic cells ranging from &lt;a href=\"basophil%20granulocyte\"&gt;basophils&lt;/a&gt; and &lt;a href=\"mast%20cells\"&gt;mast cells&lt;/a&gt; to &lt;a href=\"smooth%20muscle%20cells\"&gt;smooth muscle cells&lt;/a&gt;. The secondary functions of granzyme B are also numerous. Granzyme B has shown to be involved in inducing &lt;a href=\"inflammation\"&gt;inflammation&lt;/a&gt; by stimulating &lt;a href=\"cytokine\"&gt;cytokine&lt;/a&gt; release and is also involved in &lt;a href=\"extracellular%20matrix\"&gt;extracellular matrix&lt;/a&gt; remodelling.\nElevated levels of granzyme B are also implicated in a number of &lt;a href=\"autoimmune%20diseases\"&gt;autoimmune diseases&lt;/a&gt;, several skin diseases, and &lt;a href=\"type%201%20diabetes\"&gt;type 1 diabetes&lt;/a&gt;.\nStructure.\nIn humans, granzyme B is encoded by GZMB on chromosome 14q.11.2, which is 3.2kb long and consists of 5 &lt;a href=\"exons\"&gt;exons&lt;/a&gt;. It is one of the most abundant granzymes of which there are 5 in humans and 10 in mice. Granzyme B is thought to have evolved from a &lt;a href=\"granzyme%20H\"&gt;granzyme H&lt;/a&gt; related precursor and is more effective at lower concentrations than the other granzymes.\nThe enzyme is initially in an inactive precursor &lt;a href=\"zymogen\"&gt;zymogen&lt;/a&gt; form, with an additional &lt;a href=\"N-terminus\"&gt;amino terminal&lt;/a&gt; peptide sequence. This sequence can be cleaved by &lt;a href=\"cathepsin%20C\"&gt;cathepsin C&lt;/a&gt;, removing 2 &lt;a href=\"amino%20acids\"&gt;amino acids&lt;/a&gt;. &lt;a href=\"Cathepsin%20H\"&gt;Cathepsin H&lt;/a&gt; has also been reported to activate granzyme B.\nGranzyme B's structure consists of two 6 stranded &lt;a href=\"%CE%B2%20sheets\"&gt;\u03b2 sheets&lt;/a&gt; with 3 trans domain segments. In the granules of cytotoxic lymphocytes the enzyme can exist in two &lt;a href=\"glycosylation\"&gt;glycosylated&lt;/a&gt; forms. The high mannose form weighs 32kDa and the complex form, 35kDa.\nGranzyme B contains the &lt;a href=\"catalytic%20triad\"&gt;catalytic triad&lt;/a&gt; &lt;a href=\"histidine\"&gt;histidine&lt;/a&gt;-&lt;a href=\"aspartic%20acid\"&gt;aspartic acid&lt;/a&gt;-&lt;a href=\"serine\"&gt;serine&lt;/a&gt; in its &lt;a href=\"active%20site\"&gt;active site&lt;/a&gt; and preferentially cleaves after an &lt;a href=\"aspartic%20acid\"&gt;aspartic acid&lt;/a&gt; residue situated in the P1 position. The aspartic acid residue to be cleaved associates with an &lt;a href=\"arginine\"&gt;arginine&lt;/a&gt; residue in the enzyme's binding pocket.\nGranzyme B is active at a neutral &lt;a href=\"pH\"&gt;pH&lt;/a&gt; and is therefore inactive in the acidic CTL granules. The enzyme is also rendered inactive when bound by &lt;a href=\"SRGN\"&gt;serglycin&lt;/a&gt; in the granules to avoid apoptosis triggering inside the cytotoxic T cells themselves.\nDelivery.\nGranzyme B is released with perforin which inserts into a target cell's &lt;a href=\"plasma%20membrane\"&gt;plasma membrane&lt;/a&gt; forming a &lt;a href=\"Ion%20channel%20pore\"&gt;pore&lt;/a&gt;. Perforin has a radius of 5.5\u00a0nm and granzyme B has a &lt;a href=\"stokes%20radius\"&gt;stokes radius&lt;/a&gt; of 2.5\u00a0nm and can therefore pass through the perforin pore into the target to be destroyed.\nAlternatively, once released, granzyme B can bind to negatively charged &lt;a href=\"heparan%20sulphate\"&gt;heparan sulphate&lt;/a&gt; containing receptors on a target cell and become &lt;a href=\"endocytosis\"&gt;endocytosed&lt;/a&gt;. The &lt;a href=\"Vesicle%20%28biology%20and%20chemistry%29\"&gt;vesicles&lt;/a&gt; that carry the enzyme inside then burst, exposing granzyme b to the &lt;a href=\"cytoplasm\"&gt;cytoplasm&lt;/a&gt; and its &lt;a href=\"substrate%20%28biochemistry%29\"&gt;substrates&lt;/a&gt;. &lt;a href=\"Hsp70\"&gt;Hsp-70&lt;/a&gt; has also been linked to aiding granzyme B entry.\nGranzyme B has also been proposed to enter a target by first exchanging its bound serglycin for negative &lt;a href=\"phospholipids\"&gt;phospholipids&lt;/a&gt; in a target's plasma membrane. Entry then occurs by the less selective process of &lt;a href=\"pinocytosis\"&gt;absorptive pinocytosis&lt;/a&gt;.\nGranzyme B Mediated Apoptosis.\nOnce inside the target cell, granzyme B can cleave and activate initiator caspases &lt;a href=\"caspase%208\"&gt;8&lt;/a&gt; and &lt;a href=\"caspase%2010\"&gt;10&lt;/a&gt;, and executioner caspases &lt;a href=\"caspase%203\"&gt;3&lt;/a&gt; and &lt;a href=\"caspase%207\"&gt;7&lt;/a&gt; which trigger apoptosis. Caspase 7 is the most sensitive to granzyme B and caspases 3, 8, and 10 are only cleaved to intermediate fragments and need further cleavage for full activation.\nGranzyme B can also cleave &lt;a href=\"BH3%20interacting-domain%20death%20agonist\"&gt;BID&lt;/a&gt; leading to &lt;a href=\"Bcl-2-associated%20X%20protein\"&gt;BAX&lt;/a&gt;/&lt;a href=\"Bcl-2%20homologous%20antagonist%20killer\"&gt;BAK&lt;/a&gt; &lt;a href=\"oligomerisation\"&gt;oligomerisation&lt;/a&gt; and &lt;a href=\"cytochrome%20c\"&gt;cytochrome c&lt;/a&gt; release from the &lt;a href=\"mitochondria\"&gt;mitochondria&lt;/a&gt;. Granzyme B can cleave &lt;a href=\"Inhibitor%20of%20caspase-activated%20DNase\"&gt;ICAD&lt;/a&gt; leading to DNA fragmentation and the &lt;a href=\"DNA%20laddering\"&gt;laddering pattern&lt;/a&gt; associated with apoptosis.\nGranzyme B has a potential of over 300 substrates and can cleave &lt;a href=\"Mcl-1\"&gt;Mcl-1&lt;/a&gt; in the &lt;a href=\"outer%20mitochondrial%20membrane\"&gt;outer mitochondrial membrane&lt;/a&gt; relieving its inhibition of &lt;a href=\"BCL2L11\"&gt;Bim&lt;/a&gt;. Bim stimulates BAX/BAK oligomerisation, mitochondrial membrane permeability and apoptosis. Granzyme B can also cleave &lt;a href=\"HAX1\"&gt;HAX1&lt;/a&gt; (Hs-1 associated protein X-1) to facilitate mitochondria polarisation.\nGranzyme B can also generate a cytotoxic level of mitochondrial &lt;a href=\"reactive%20oxygen%20species\"&gt;reactive oxygen species&lt;/a&gt; (ROS) to mediate cell death. The caspase independent pathways of cell death are thought to have arisen to overcome &lt;a href=\"viruses\"&gt;viruses&lt;/a&gt; that can inhibit caspases and prevent apoptosis.\nTargets.\nNucleus.\nGranzyme B has many substrates located in the &lt;a href=\"Cell%20nucleus\"&gt;nucleus&lt;/a&gt;. Granzyme B can cleave &lt;a href=\"Poly%20ADP%20ribose%20polymerase\"&gt;PARP&lt;/a&gt; (poly ADP ribose polymerase) and &lt;a href=\"DNA-PKcs\"&gt;DNA PK&lt;/a&gt; (DNA protein kinase) to disrupt DNA repair and &lt;a href=\"retrovirus\"&gt;retroviral&lt;/a&gt; DNA integration. Granzyme B can also cleave &lt;a href=\"nucleophosmin\"&gt;nucleophosmin&lt;/a&gt;, &lt;a href=\"topoisomerase%201\"&gt;topoisomerase 1&lt;/a&gt; and &lt;a href=\"nucleolin\"&gt;nucleolin&lt;/a&gt; to prevent viral replication.\nGranzyme B can cleave ICP4 from the &lt;a href=\"Herpes%20simplex%20virus\"&gt;HSV 1&lt;/a&gt; virus which is an essential protein used for gene &lt;a href=\"transactivation\"&gt;transactivation&lt;/a&gt; and &lt;a href=\"nuclear%20mitotic%20apparatus%20protein%201\"&gt;NUMA&lt;/a&gt; (Nuclear mitotic apparatus protein) can be cleaved to prevent &lt;a href=\"mitosis\"&gt;mitosis&lt;/a&gt;.\nGranzyme B can also cleave &lt;a href=\"DNA-binding%20protein\"&gt;DBP&lt;/a&gt; (DNA Binding Protein) into a 50 kDa fragment and then into an additional 60 kDa indirectly through the caspases it activates.\nExtracellular Matrix.\nGranzyme B can degrade many proteins in the extracellular matrix (ECM) including &lt;a href=\"fibronectin\"&gt;fibronectin&lt;/a&gt;, &lt;a href=\"vitronectin\"&gt;vitronectin&lt;/a&gt; and &lt;a href=\"aggrecan\"&gt;aggrecan&lt;/a&gt;. Cleavage can cause cell death by &lt;a href=\"anoikis\"&gt;anoikis&lt;/a&gt; and release alarmins from the ECM inducing inflammation. Fragments of fibronectin can attract &lt;a href=\"neutrophils\"&gt;neutrophils&lt;/a&gt; and stimulate &lt;a href=\"Matrix%20metalloproteinase\"&gt;MMP&lt;/a&gt; expression from &lt;a href=\"chondrocytes\"&gt;chondrocytes&lt;/a&gt;. Basophils secrete granzyme B to degrade &lt;a href=\"endothelium\"&gt;endothelial&lt;/a&gt; cell-cell contacts allowing &lt;a href=\"extravasation\"&gt;extravasation&lt;/a&gt; to sites of inflammation.\nGranzyme B can also induce inflammation by processing cytokines &lt;a href=\"IL1A\"&gt;IL-1\u03b1&lt;/a&gt; and &lt;a href=\"Interleukin%2018\"&gt;IL18&lt;/a&gt;. It can also trigger the release of &lt;a href=\"Interleukin%206\"&gt;IL6&lt;/a&gt; and &lt;a href=\"Interleukin%208\"&gt;IL8&lt;/a&gt; through activation of &lt;a href=\"Coagulation%20factor%20II%20receptor\"&gt;PAR1&lt;/a&gt; (Protease activated receptor 1).\nCleavage of vitronectin occurs at the RGD &lt;a href=\"integrin\"&gt;integrin&lt;/a&gt; binding site interrupting cell growth signalling pathways. Cleavage of &lt;a href=\"laminin\"&gt;laminin&lt;/a&gt; and fibronectin disrupts &lt;a href=\"dermoepidermal%20junction\"&gt;dermal-epidermal junction&lt;/a&gt; attachment and cross talk while decorin destruction by granzyme B causes &lt;a href=\"collagen\"&gt;collagen&lt;/a&gt; disorganisation, skin thinning and aging. &lt;a href=\"Keratinocytes\"&gt;Keratinocytes&lt;/a&gt; can express granzyme B after exposure to &lt;a href=\"ultraviolet\"&gt;UVA&lt;/a&gt; and &lt;a href=\"ultraviolet\"&gt;UVB&lt;/a&gt; which is linked to &lt;a href=\"photoaging\"&gt;photoaging&lt;/a&gt; of the skin.\nGranzyme B can also impair wound healing. Cleavage of the &lt;a href=\"von%20Willebrand%20factor\"&gt;von Willebrand factor&lt;/a&gt; inhibits &lt;a href=\"platelet\"&gt;platelet&lt;/a&gt; aggregation and of &lt;a href=\"plasminogen\"&gt;plasminogen&lt;/a&gt; produces an &lt;a href=\"angiostatin\"&gt;angiostatin&lt;/a&gt; fragment preventing &lt;a href=\"angiogenesis\"&gt;angiogenesis&lt;/a&gt;. The cutting of fibronectins and vitronectins delays the formation of a provisional matrix impairing wound healing further.\nT cell Regulation.\nGranzyme B is secreted by &lt;a href=\"regulatory%20T%20cells\"&gt;regulatory T cells&lt;/a&gt; to kill &lt;a href=\"CD4\"&gt;CD4&lt;/a&gt;+ T cells that have not been exposed to host cells that are restricted to the peripheral tissues and cannot reach the &lt;a href=\"thymus\"&gt;thymus&lt;/a&gt;. This &lt;a href=\"activation-induced%20cell%20death%20%28AICD%29\"&gt;activation-induced cell death (AICD)&lt;/a&gt; can be achieved without the &lt;a href=\"Fas%20receptor\"&gt;Fas&lt;/a&gt; death pathway and prevents &lt;a href=\"autoimmunity\"&gt;autoimmune reaction&lt;/a&gt; to &lt;a href=\"antigen\"&gt;self antigens&lt;/a&gt;.\nInhibitors.\nGranzyme B's most common inhibitor is &lt;a href=\"SERPINB9\"&gt;SERPINB9&lt;/a&gt; also known as proteinase inhibitor nine (PI-9) which is 376 amino acids long and found in the nucleus and cytoplasm.\nIt is produced by many types of cell to protect themselves from accidental granzyme B mediated cell death. PI-9 is &lt;a href=\"metastability\"&gt;metastable&lt;/a&gt; and forms an energetically favourable conformation when bound to granzyme B. The reactive loop centre (RCL) of the PI-9 molecule acts as a pseudosubstrate and initially forms a reversible Michaelis complex. Once the &lt;a href=\"peptide%20bond\"&gt;peptide bond&lt;/a&gt; of the RCL is cleaved between positions P1 and P1', granzyme B is permanently inhibited.\nHowever, if the RCL is cleaved efficiently, PI-9 does not act as a 1:1 &lt;a href=\"suicide%20inhibition\"&gt;suicide substrate&lt;/a&gt; and granzyme B is left uninhibited. &lt;a href=\"GZMM\"&gt;Granzyme M&lt;/a&gt; can also cleave PI-9 in the nucleus and cytoplasm to relieve granzyme B of inhibition.\nProtein L4-100K from &lt;a href=\"adenoviridae\"&gt;adenoviruses&lt;/a&gt; can also inhibit granzyme B by binding at &lt;a href=\"exosite\"&gt;exosite&lt;/a&gt;s and specific binding pockets. L4-100K is an assembly protein that can transport &lt;a href=\"capsomere\"&gt;hexon capsomeres&lt;/a&gt; into the nucleus of an adenovirus. 100k can be cleaved to a 90kDa fragment by &lt;a href=\"granzyme%20H\"&gt;granzyme H&lt;/a&gt; to relieve this inhibition which is important in adenovirus 5 infected cells.\nRole in Disease.\nGranzyme B has a normal concentration of 20-40 pg/ml in the &lt;a href=\"blood%20plasma\"&gt;blood plasma&lt;/a&gt; while retaining 70% activity and elevated concentrations of granzyme B are found in a number of disease states.\nGranzyme B can generate autoantigens by cleaving in disordered regions and linker regions of antigens exposing new &lt;a href=\"epitopes\"&gt;epitopes&lt;/a&gt; and this can cause the development of autoimmune diseases.\nGranzyme B release with perforin from &lt;a href=\"CD8\"&gt;CD8+&lt;/a&gt; T cells can cause &lt;a href=\"heart\"&gt;heart&lt;/a&gt; and &lt;a href=\"kidney\"&gt;kidney&lt;/a&gt; &lt;a href=\"transplant%20rejection\"&gt;transplant rejection&lt;/a&gt; through killing of allogeneic endothelial cells. The destruction of &lt;a href=\"insulin\"&gt;insulin&lt;/a&gt; producing &lt;a href=\"beta%20cell\"&gt;\u03b2 cells&lt;/a&gt; in &lt;a href=\"islets%20of%20Langerhans\"&gt;pancreatic islets&lt;/a&gt; is mediated by T cells and granzyme B contributing to Type 1 Diabetes. Granzyme B can also mediate the death of cells after &lt;a href=\"spinal%20cord%20injury\"&gt;spinal cord injury&lt;/a&gt; and is found at elevated levels in &lt;a href=\"rheumatoid%20arthritis\"&gt;rheumatoid arthritis&lt;/a&gt;.\n&lt;a href=\"Chronic%20obstructive%20pulmonary%20disease\"&gt;COPD&lt;/a&gt; (Chronic Obstructive Pulmonary Disease) has been attributed to granzyme B secreted from NK and T cells causing the apoptosis of &lt;a href=\"respiratory%20epithelium\"&gt;bronchial epithelial cells&lt;/a&gt;. Matrix destabilisation and remodelling by granzyme B is also linked to &lt;a href=\"asthma\"&gt;asthma&lt;/a&gt; pathogenesis. \nGranzyme B can kill &lt;a href=\"melanocytes\"&gt;melanocytes&lt;/a&gt; causing the skin condition &lt;a href=\"vitiligo\"&gt;vitiligo&lt;/a&gt; and granzyme B overexpression is found in &lt;a href=\"contact%20dermatitis\"&gt;contact dermatitis&lt;/a&gt;, &lt;a href=\"lichen%20sclerosus\"&gt;lichen sclerosus&lt;/a&gt; and &lt;a href=\"lichen%20planus\"&gt;lichen planus&lt;/a&gt; cases.\nCytotoxic cells expressing granzyme B have been identified close to &lt;a href=\"hair%20follicles\"&gt;hair follicles&lt;/a&gt; linking a possible role in hair loss.\nThe ECM remodelling properties of granzyme B have also implicated its involvement in &lt;a href=\"ventricular%20remodeling\"&gt;left ventricular remodelling&lt;/a&gt;, which increases the subsequent chances of &lt;a href=\"myocardial%20infarction\"&gt;myocardial infarction&lt;/a&gt;. The weakening of the &lt;a href=\"fibrous%20cap\"&gt;fibrous cap&lt;/a&gt; of &lt;a href=\"atheroma\"&gt;atheromatous plaques&lt;/a&gt; by apoptosis of smooth muscle cells has also been linked to granzyme B."
}